About

Brian Parker joined GeminiBio in July of 2021 and was previously at Thermo Fisher Scientific where he was Vice President and General Manager of the Production Chemicals and Services business unit within the Bioproduction Division.  While leading the Production Chemicals and Services business, Brian reversed two years of negative organic growth by developing and commercializing new products and solutions to better serve global bioproduction customers, as well as expanding the business’ reach into all global regions.

Prior to joining Thermo Fisher in 2017, Brian grew, turned around, and started a wide range of healthcare technology and services businesses, including growing US Oncology’s pharmaceutical services business from $133M to $543M, as well as developing and commercializing novel technology and clinical service solutions that enabled primary care physicians and oncologists to manage value-based reimbursement models for Aetna and Integra Connect respectively.

Prior to starting his business career, Brian served in the US Army’s 6^th Infantry Division as a Military Intelligence Officer.

Brian attended the University of Alaska on a military scholarship and earned a BA in History.

Ed Mendham, CPA, MBA joined GeminiBio in August 2021 and had previously served as Chief Financial Officer of Simply Beautiful Smiles, a dental service organization with locations in southeastern Pennsylvania and New Jersey.

Prior to Simply Beautiful Smiles, he served as Vice President, Finance – Portfolio Companies for BelHealth Investment Partners, supporting the financial due diligence in both portfolio and add-on acquisitions while working directly with portfolio company finance teams to drive liquidity and reporting.

Previously, he was Chief Financial Officer of Qforma, a BelHealth portfolio company and global provider of key opinion leader solutions and launch management solutions for the life sciences industry.

Prior to Qforma, he served as Vice President, Finance of Advanced Health Media, an industry leading provider of software solutions, sales force logistics and outsourced speaker bureau management for the pharmaceutical industry.

Ed graduated from Trenton State College (The College of New Jersey) with a BS in Accountancy and earned his MBA from Rider University.

Robert Perry joined GeminiBio in October 2019 as the Chief Operating Officer and moved to the Chief Scientific Officer role in July 2021.  Prior to GeminiBio, Robert was Sr. Director at Atara Biotherapeutics.

At Atara, Robert had responsibility for building their state of the art manufacturing facility in Thousand Oaks, CA, briefly led their external manufacturing and established and ran their materials science group.

Prior to Atara, Robert was a co-founder and Vice President of Manufacturing and Logistics at Athersys, Inc responsible for technology transfer of technologies into the company, production and international distribution of clinical trial materials for late-stage development cell therapy product.

Robert has designed and overseen capital building projects for life sciences companies in excess of $50MM. He is a frequent guest lecturer and has authored multiple book chapters on GMP manufacturing, logistics and regulatory compliance of cell therapy products.

Robert earned his BS in Microbiology from CalPoly, San Luis Obispo, CA.

Justin Henson joined GeminiBio in September of 2020 and was previously at Thermo Fisher Scientific where he was the Sr. Director of Global Commercial Operations for the Bioproduction Division.

Prior to working at Thermo Fisher, he worked at Avantor for 16 years where he held various sales leadership roles including the VP of Sales for North America, overseeing the Production and Research sales teams, and managing business sold directly to biotech and research institutions, as well as through distribution partners.

He has earned his Lean Certification, through Villanova University’s Six Sigma Program, and has developed sales operations programs geared toward driving key behaviors and streamlining effectiveness within commercial organizations.  He has developed sales training programs that focus on continuous learning platforms to drive sales effectiveness and develop a technical understanding of the products and markets served.

Justin earned a BS in Biomedical Sciences from Texas A&M University.

David Terry joined GeminiBio in February of 2023 and was previously at Cytiva where he was a Process Liquid and Buffer Specialist following the Danaher acquisition of Intermountain Life Sciences (ILS). While at Cytiva, David focused on driving  continued growth of the legacy ILS business as well as participating in the overall growth strategy of the Cytiva process liquid division.

Prior to the acquisition of Intermountain Life Sciences by Cytiva, David served as a Bioprocess Specialist at ILS playing a major role in the growth of the business leading to the Danaher acquisition in 2021.

Before beginning his career in the life sciences industry David played collegiate and professional tennis and functioned as a director of tennis of multiple successful tennis programs around the US.

David earned a bachelors degree in criminology from West Virginia State University

Patricia Cazcarro joined GeminiBio in October 2020 and was previously the Quality Manager for a FDA cGMP regulated manufacturing plant and was responsible for testing and release (chemistry, microbiology, and packaging specifications), material disposition, auditing, root cause analysis & CAPA in a large-scale manufacturing environment.

Patricia has extensive experience manufacturing cGMP process liquids for the biotechnology industry gained from her time at Millipore Sigma, where she served as Manufacturing Manager for catalog and custom liquids.

Prior to joining Millipore Sigma, Patricia was Manager of Molecular Diagnostics at Enzo Clinical Labs, as well as Manager of R&D at Sanofi-Genzyme.

Patricia earned a BS in Biology and a MS in Plant Genetics from Iowa State University.